Overexpression of p53 protein and MDM2 in papillary carcinomas of the thyroid: Correlations with clinicopathologic features

被引:25
|
作者
Horie, S [1 ]
Maeta, H [1 ]
Endo, K [1 ]
Ueta, T [1 ]
Takashima, K [1 ]
Terada, T [1 ]
机构
[1] Tottori Univ, Fac Med, Dept Pathol 2, Yonago, Tottori 6838503, Japan
关键词
immunohistochemistry; MDM2; neoplasms; p53; papillary carcinoma of the thyroid;
D O I
10.1046/j.1440-1827.2001.01159.x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Expression of p53 protein and MDM2 was evaluated in paraffin-embedded tissue from 78 patients with papillary carcinomas of the thyroid (PCT), in order to elucidate the relationship between them and their correlations with some clinicopathologic features implicated in tumor progression. These proteins were expressed in nuclei of tumor cells, but not in non-tumor cells. Staining was defined as positive when 10% or more of tumor cells expressed these proteins. The number of cases positive for p53 protein was 21/78 (27%), and that positive for MDM2 was 26/78 (33%). Co-overexpression of p53 protein and MDM2 was observed in 12/78 cases (15%). A significant positive relationship was found between them (P < 0.01); p53-positive cases tended to be also positive for MDM2 and vice versa. Statistical analysis revealed that overexpression of p53 protein significantly correlated with large tumor size (P = 0.0271) and the presence of capsular invasion (P = 0.04). There were significant positive correlations between tumor size and intrathyroidal invasion and between tumor size and capsular invasion in PCT, suggesting that p53 protein overexpression is associated only with tumor progression (tumor size). However, we could not find any significant correlations between MDM2 expression and clinicopathologic features. Our findings suggest that overexpression of p53 protein and MDM2 in papillary carcinoma of the thyroid is associated with the progression of the tumors, and that p53 may be a marker of the progression of PCT.
引用
收藏
页码:11 / 15
页数:5
相关论文
共 50 条
  • [21] p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53
    Christine Wasylyk
    Roberto Salvi
    Manuela Argentini
    Christine Dureuil
    Isabelle Delumeau
    Joseph Abecassis
    Laurent Debussche
    Bohdan Wasylyk
    Oncogene, 1999, 18 : 1921 - 1934
  • [22] p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53
    Wasylyk, C
    Salvi, R
    Argentini, M
    Dureuil, C
    Delumeau, I
    Abecassis, J
    Debussche, L
    Wasylyk, B
    ONCOGENE, 1999, 18 (11) : 1921 - 1934
  • [23] The expression of MDM2 and p53 protein breast carcinoma
    Hideshima, T
    Shinohara, T
    Baba, M
    Shirakusa, T
    ONCOLOGY REPORTS, 1997, 4 (02) : 297 - 300
  • [24] P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome
    Jeczen, Ryszard
    Skomra, Danuta
    Cybulski, Marek
    Schneider-Stock, Regine
    Szewczuk, Wiktor
    Roessner, Albert
    Rechberger, Tomasz
    Semczuk, Andrzej
    CLINICAL & EXPERIMENTAL METASTASIS, 2007, 24 (07) : 503 - 511
  • [25] p53 AND MDM2 PROTEIN EXPRESSION IN ACTINIC CHEILITIS
    Andrade de Freitas, Maria da Conceicao
    Pedreira Ramalho, Luciana Maria
    Aquino Xavier, Flavia Calo
    Gomes Moreira, Andre Luis
    Almeida Reis, Silvia Regina
    JOURNAL OF APPLIED ORAL SCIENCE, 2008, 16 (06) : 414 - 419
  • [26] P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome
    Ryszard Jeczen
    Danuta Skomra
    Marek Cybulski
    Regine Schneider-Stock
    Wiktor Szewczuk
    Albert Roessner
    Tomasz Rechberger
    Andrzej Semczuk
    Clinical & Experimental Metastasis, 2007, 24 : 503 - 511
  • [27] Strong correlation of basement membrane degradation with p53 inactivation and/or mdm2 overexpression in superficial urothelial carcinomas
    Ozdemir, E
    Kakehi, Y
    Okuno, H
    Habuchi, T
    Okada, Y
    Yoshida, O
    JOURNAL OF UROLOGY, 1997, 158 (01): : 206 - 211
  • [28] Nuclear accumulation of MDM2 protein in well-differentiated papillary thyroid carcinomas
    Jennings, T
    Bratslavsky, G
    Gerasimov, G
    Troshina, K
    Bronstein, M
    Dedov, I
    Alexandrova, G
    Figge, J
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 1995, 62 (03) : 199 - 206
  • [29] Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors
    Yokoyama, R
    Schneider-Stork, R
    Radig, K
    Wex, T
    Roessner, A
    PATHOLOGY RESEARCH AND PRACTICE, 1998, 194 (09) : 615 - 621
  • [30] Inorganic arsenic induces MDM2, p53, and their phosphorylation and affects the MDM2/p53 complex in vitro
    Yin, Jinyao
    Zhou, Qian
    Tan, Jingwen
    Che, Wangjun
    He, Yuefeng
    ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH, 2022, 29 (58) : 88078 - 88088